πŸ‡ΊπŸ‡Έ FDA
Patent

US 11364251

Pharmaceutical formulation

granted A61KA61K31/573A61K31/58

Quick answer

US patent 11364251 (Pharmaceutical formulation) held by Semnur Pharmaceuticals, Inc. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Semnur Pharmaceuticals, Inc.
Grant date
Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/573, A61K31/58, A61K31/661, A61K45/06